CATAMARAN BIO
Catamaran Bio is a biotechnology company that specializes in allogeneic immune cell therapies. It offers cell therapy company developing allogeneic, off-the-shelf products for patients with an unmet medical need. It was founded in 2020 and headquartered in Cambridge, Massachusetts.
CATAMARAN BIO
Industry:
Biopharma Biotechnology Health Care
Founded:
2020-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.catamaranbio.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
42 M USD
Technology used in webpage:
Mimecast
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Dyno Therapeutics
Dyno Therapeutics is a biotechnology company that uses artificial intelligence for gene therapy.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Astellas Venture Management
Astellas Venture Management investment in Series A - Catamaran Bio
Lightstone Ventures
Lightstone Ventures investment in Series A - Catamaran Bio
SV Health Investors
SV Health Investors investment in Series A - Catamaran Bio
Takeda Ventures
Takeda Ventures investment in Series A - Catamaran Bio
Sofinnova Partners
Sofinnova Partners investment in Series A - Catamaran Bio
Key Employee Changes
Official Site Inspections
http://www.catamaranbio.com Semrush global rank: 4.01 M Semrush visits lastest month: 3.09 K
- Host name: 160.26.180.107.host.secureserver.net
- IP address: 107.180.26.160
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Catamaran Bio"
Company Overview - Catamaran Bio
We are driven to realize the full potential of cell therapy by powering a key type of immune cell, Natural Killer (NK) cells, with new properties to create transformative cancer treatments for more patients.See details»
About - Catamaran Bio
©2024 Catamaran Bio, Inc. All Rights Reserved. TAILWIND is a registered trademark of Catamaran Bio. Catamaran is a trademark of Catamaran Bio.See details»
Catamaran Bio - Crunchbase Company Profile & Funding
Nov 23, 2020 Catamaran Bio is a biotechnology company that specializes in allogeneic immune cell therapies. It offers cell therapy company developing allogeneic, off-the-shelf products for …See details»
CATAMARAN BIO, INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for CATAMARAN BIO, INC. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
Catamaran Bio Company Profile 2024: Valuation, Funding
Developer of allogeneic immune cell therapies designed to provide transformative off-the-shelf treatments for solid tumors and other cancers.See details»
Catamaran Bio - Company Profile & Staff Directory - ContactOut
At Catamaran, our mission is to harness the power of our proprietary TAILWINDâ„¢ Platform to develop safe and effective, off-the-shelf, allogeneic immune cell therapies for the treatment of …See details»
Catamaran Bio - workinbiotech.com
Catamaran Bio is developing off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell therapies to address a broad range of cancers. NK cells are critical components of the immune …See details»
Catamaran Bio - Products, Competitors, Financials, Employees ...
The company specializes in engineering NK (natural killer) cell therapies to provide treatments for solid tumors and other cancers. It primarily serves the healthcare sector, particularly in …See details»
Catamaran Bio selects OmniaBio as partner to develop and …
OmniaBio Inc. is a contract development and manufacturing organization (CDMO) focused on cell and gene therapies from pre-clinical through to commercialization, and a subsidiary of CCRM.See details»
Catamaran Bio - Craft
Catamaran Bio is a cell therapy company developing allogeneic, off-the-shelf products for patients with unmet medical needs. It creates drugs designed to treat a broad range of cancers, …See details»
Catamaran Bio - LinkedIn
At Catamaran, our mission is to harness the power of our proprietary TAILWINDâ„¢ Platform to develop safe and effective, off-the-shelf, allogeneic immune cell therapies for the treatment of …See details»
Catamaran Bio Inc. | Insights
Https://catamaranbio.com. Industry. Pharmaceuticals; Biotechnology. Gene Therapy, Cell Therapy; See more in Biomedtracker. Latest on Catamaran Bio Inc. Already A Biomedtracker …See details»
Catamaran Bio selects OmniaBio as partner to develop and
Mar 14, 2023 OmniaBio Inc. is a contract development and manufacturing organization (CDMO) focused on cell and gene therapies from pre-clinical through to commercialization, and a …See details»
MaxCyte Signs Strategic Platform License with Catamaran Bio to …
For more information, please visit catamaranbio.com and follow Catamaran on LinkedIn and @CatamaranBio on Twitter. MaxCyte Contacts: US IR Adviser Gilmartin Group David …See details»
Catamaran Bio CEO and Key Executive Team | Craft.co
Catamaran Bio's Chief Scientific Officer is Vipin Suri. Other executives include Maina Bhaman, Director; Caroline Gaynor, Director and 8 others. See the full leadership team at Craft.See details»
Catamaran Bio — Sofinnova Partners
Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors.See details»
Press Releases - Catamaran Bio
Nov 10, 2022 Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, today announced that the company has launched with $42 million in …See details»
Catamaran Bio selects OmniaBio as partner to develop and …
Mar 14, 2023 BOSTON & TORONTO--(BUSINESS WIRE)--Catamaran Bio Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, and OmniaBio Inc., a …See details»
Catamaran Bio Announces Preclinical Data from Allogeneic CAR …
Apr 11, 2023 Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models Data underscore potential of TAILWIND® platform to create effective CAR …See details»